BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32365768)

  • 21. Current state of Alzheimer's fluid biomarkers.
    Molinuevo JL; Ayton S; Batrla R; Bednar MM; Bittner T; Cummings J; Fagan AM; Hampel H; Mielke MM; Mikulskis A; O'Bryant S; Scheltens P; Sevigny J; Shaw LM; Soares HD; Tong G; Trojanowski JQ; Zetterberg H; Blennow K
    Acta Neuropathol; 2018 Dec; 136(6):821-853. PubMed ID: 30488277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.
    Galozzi S; Marcus K; Barkovits K
    Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
    Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
    Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
    Khan TK; Alkon DL
    J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
    Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
    Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
    Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
    Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.